- Report
- March 2024
- 30 Pages
Global
From €2482EUR$2,750USD£2,150GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4467EUR$4,950USD£3,871GBP
- Report
- January 2025
- 250 Pages
Global
From €4511EUR$4,999USD£3,909GBP
- Report
- May 2024
- 160 Pages
Global
From €4484EUR$4,969USD£3,886GBP
- Report
- May 2025
- 120 Pages
Global
From €4286EUR$4,750USD£3,714GBP
- Report
- February 2024
- 115 Pages
Global
From €4286EUR$4,750USD£3,714GBP
- Report
- June 2025
- 209 Pages
Global
From €2256EUR$2,500USD£1,955GBP
- Report
- April 2025
- 251 Pages
Global
From €2256EUR$2,500USD£1,955GBP
- Report
- November 2024
- 39 Pages
Global
From €3605EUR$3,995USD£3,124GBP
- Report
- February 2023
- 1359 Pages
Global
From €2256EUR$2,500USD£1,955GBP
- Report
- May 2018
- 127 Pages
Global
From €13531EUR$14,995USD£11,725GBP
- Report
- November 2023
- 150 Pages
Global
From €4377EUR$4,850USD£3,792GBP
- Report
- January 2025
- 21 Pages
Global
From €16239EUR$17,995USD£14,071GBP
- Report
- May 2025
- 130 Pages
Global
From €4377EUR$4,850USD£3,792GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €13531EUR$14,995USD£11,725GBP
- Report
- December 2022
- 42 Pages
Global
From €3158EUR$3,500USD£2,737GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,155USD£3,139GBP
- Report
- November 2025
- 132 Pages
Global
From €857EUR$950USD£743GBP
- Report
- January 2025
- 132 Pages
Global
From €857EUR$950USD£743GBP

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life.
The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more